Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma.

about

Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma.

Item

http://www.wikidata.org/entity/Q52775079

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Ribonucleotide Reductase Catal ...... ic Target in Multiple Myeloma.

@en

Ribonucleotide Reductase Catalytic Subunit M1

@nl

type

Item

label

Ribonucleotide Reductase Catal ...... ic Target in Multiple Myeloma.

@en

Ribonucleotide Reductase Catalytic Subunit M1

@nl

prefLabel

Ribonucleotide Reductase Catal ...... ic Target in Multiple Myeloma.

@en

Ribonucleotide Reductase Catalytic Subunit M1

@nl

P1476

Ribonucleotide Reductase Catal ...... ic Target in Multiple Myeloma.

@en

P2093

Hiroto Ohguchi

http://www.w3.org/2001/XMLSchema#string

Masahiro Kizaki

http://www.w3.org/2001/XMLSchema#string

Mehmet K Samur

http://www.w3.org/2001/XMLSchema#string

Morihiko Sagawa

http://www.w3.org/2001/XMLSchema#string

Nikhil C Munshi

http://www.w3.org/2001/XMLSchema#string

Takeshi Harada

http://www.w3.org/2001/XMLSchema#string

Teru Hideshima

http://www.w3.org/2001/XMLSchema#string

Yu-Tzu Tai

http://www.w3.org/2001/XMLSchema#string

P2860

Use of the γ-H2AX assay to monitor DNA damage and repair in translational cancer research

Clinical significance of TP53 mutation in myeloma.

ATM and ATR: networking cellular responses to DNA damage

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1.

Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers.

p53 abnormalities and potential therapeutic targeting in multiple myeloma.

New strategies in the treatment of multiple myeloma.

P304

5225-5237

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-17-0263

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth C Anderson

P577

2017-04-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28442502

http://www.w3.org/2001/XMLSchema#string

P932

5581671

http://www.w3.org/2001/XMLSchema#string